#USA #Class Action #Securities Fraud #Radnor #GeneDx Holdings

Investors Urged to Act: Class Action Lawsuit Filed Against GeneDx Holdings Corp

A class action lawsuit has been initiated against GeneDx Holdings Corp. (NASDAQ: WGS) concerning alleged securities fraud, inviting investors who purchased shares between April 16, 2025, and May 4, 2026, to take action. The deadline to seek lead plaintiff status is August 3, 2026. This legal action is being spearheaded by Kessler Topaz Meltzer & Check, LLP, a well-known name in securities litigation, suggesting that affected investors may have viable claims for recovery.

Background of the Lawsuit

The lawsuit centers on claims that GeneDx Holdings made materially false statements and failed to disclose pertinent facts about the company’s acquisition of Fabric Genomics. GeneDx had announced a deal worth up to $51 million in early 2025 to incorporate Fabric Genomics, a company specializing in AI-driven genomic interpretation, into its operations. This acquisition was touted by GeneDx as a pathway to expanding its market and creating scalable revenue streams.

However, during the class period, it was disclosed that Fabric faced significant viability issues, casting doubt on GeneDx's optimistic projections. The complaint argues that the defendants misrepresented the company's operational status, which misled investors regarding the company's financial health.

The Share Price Drop

A significant turning point came on May 4, 2026, when GeneDx disclosed its 2026 first-quarter results. The report showcased a drop in adjusted gross margin, lowered projected earnings, and revealed that the average reimbursement rate fell short of expectations. Additionally, the company reported a staggering impairment loss of $31.3 million directly linked to the Fabric acquisition. These disclosures resulted in a dramatic decline of over 49% in GeneDx's share price, alarmingly impacting shareholders.

Filing for Lead Plaintiff Status

Investors who purchased shares during the specified period are urged to consider filing for lead plaintiff status by August 3, 2026. This status enables an investor to represent the class in directing the lawsuit. For those who might be interested in pursuing legal action against GeneDx Holdings, Kessler Topaz Meltzer & Check, LLP provides an opportunity to discuss potential claims at no cost or obligation. Interested parties can reach out to Jonathan Naji, Esq., for direct consultation.

The law firm operates on a contingency fee basis, alleviating any initial financial burdens from investors seeking to reclaim their losses. It is important to note that becoming a lead plaintiff will not affect the ability to claim a share of any recovery from the lawsuit.

Next Steps for Affected Investors

Investors who have incurred losses on GeneDx stock should:
1. Consider applying for lead plaintiff status by the given deadline.
2. Reach out to Kessler Topaz Meltzer & Check, LLP for a free case evaluation.
3. Decide whether to retain counsel of choice or remain an absent member of the class.

As a leading firm in securities litigation, Kessler Topaz Meltzer & Check, LLP has secured substantial recoveries for investors, fostering a reputation that underscores their commitment to client representation. Now is the time for GeneDx investors to act if they feel wronged by the company’s disclosures and current financial standing.

Conclusion

The GeneDx Holdings class action lawsuit serves as a critical reminder for investors to remain vigilant regarding the disclosures made by public companies they invest in, particularly in relation to acquisitions and financial health. This case presents an opportunity for affected shareholders to potentially recover some of their losses. Interested parties are strongly encouraged to act swiftly before the deadline, ensuring their voices are heard in court.